Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 7426

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Assay
  • Diagnostic
  • Drug Discovery
  • Biotechnology
  • Therapeutic
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7426

License Grant
This in-License of RXDX-101 and RXDX-102 from the Licensor, an Italian state-owned biopharmaceutical company, grants the Licensee exclusive global rights to develop and commercialize RXDX-101 and RXDX-102.

The development rights under the License Agreement are exclusive for the term of the Agreement with respect to RXDX-101 and RXDX-102 and also, as to the Licensor, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of RXDX-101 and RXDX-102, and include the right to grant subLicenses.

License Property
RXDX-101 is a tyrosine kinase inhibitor directed to the TrkA, ROS1 and ALK proteins, which is in a Phase I/II clinical study in molecularly defined patient populations for the treatment of solid tumors.

RXDX-102 is a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, TrkA, TrkB and TrkC, which is currently in preclinical development for the treatment of multiple cancers. Tyrosine kinases are enzymes that transfer phosphate groups from adenosine triphosphate (ATP) to cellular proteins and can function as an on/off switch for cellular functions, including cancer signaling.

IPSCIO Record ID: 289175

License Grant
For the Commercial License to Clinical Candidates and Corresponding Products, Licensor grant an exclusive license, with the right to grant and authorize sublicenses through multiple tiers, under the Licensor Technology and Licensors interest in the applicable Collaboration Technology, to make, have made, use, offer for sale, sell, import, export and otherwise exploit Active Compounds, Clinical Candidates, Lead Compounds and Products for use in the Field and in the Territory.
License Property
The Parties have each identified multiple oncology kinase targets that have the potential to be used as the basis for drug discovery programs.

Active Compound shall mean a Compound that modulates a Target, the mechanism of which is a binding interaction with a Target, having a level of activity against a Target, expressed as an IC50, that is – less than forty (40) nanomolar- as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan; and a Compound that modulates at least two of the following receptors TrkA, TrkB or TrkC, the mechanism of which is a binding interaction with the applicable Trk receptor, having a level of activity against the applicable Trk receptor, expressed as an ICso, that is less than forty (40) nanomolar as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan.

Clinical Candidate shall mean, with respect to each Target or Trk, any Active Compound that meets the Clinical Candidate Criteria set forth in the Discovery Plan.

Compound shall mean any one or more chemical entity(ies) made and tested against Trk in the course of Licensors pan-Trk program prior to the Effective Date, or synthesized by Licensor in the course of performing or in connection with the Discovery Program, in each case together with any salt, hydrate, solvate, clathrate, polymorph or isomer thereof.

Product shall mean any pharmaceutical product incorporating as an active ingredient an Active Compound.

Trk shall mean the Trk family of receptors TrkA, Tr kB and TrkC.
—  TrkA shall mean the protein known as UniProtKB/Swiss-Prot # P04629.
—  TrkB shall mean the protein known as UniProtKB/Swiss-Prot # Q16620.
—  TrkC shall mean the protein known as UniProtKB/Swiss-Prot # Q16288.

The Targets are
—  The protein family commonly known as Firbroblast Growth Factor Receptors (FGFR),
—  The protein commonly known as [p70S6 Kinase], identified with the following SwissProt entries
a) Ribosomal protein S6 kinase beta-1 (P23443)
b) Ribosomal rotein S6 kinase beta-2 (Q9UBS0]—  The protein commonly known as Telomerase reverse transcriptase, identified with the following SwissProt entries
a) Telomerase reverse transcriptase (014746)
b) Telomerase protein component 1 (Q99973)

Field of Use
The development and commercialization agreement pertain to certain Array-invented compounds targeted at a specified novel oncogenic activating mutation.

Licensee possesses pharmaceutical research, development and commercialization capabilities, as well as proprietary technology in the field of cancer treatment.

IPSCIO Record ID: 359490

License Grant
The Chinese Licensor and Licensee collaborated on the sale for ORPATHYS® (savolitinib) in China.  Licensor is responsible for the clinical development, marketing authorization, manufacturing and supply of ORPATHYS® in China, while Licensee is responsible for its commercialization on China sales.
License Property
ORPATHYS® (savolitinib), an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase.

ORPATHYS® is an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”) that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations) or gene amplification.

The Phase II trial is an open-label, two-cohort, multi-center study to evaluate the efficacy, safety and pharmacokinetics (“PK”) of ORPATHYS® in locally advanced or metastatic GC or GEJ patients whose disease progressed after at least one line of standard therapy.

Field of Use
Field of use is for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”).

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.

IPSCIO Record ID: 329688

License Grant
Licensor, a non-profit teaching hospital, grants an exclusive license under Licensors rights in the Patent Rights to make, have made, use, have used, Sell, have Sold, import and have imported Patented Products and Patented Uses.   Licensor grants the right to  grant sublicenses.
License Property
The Patent application is entitled ALK-Fc exhibits activity in Renal cancer murine xenografts as a single agent and in combination with VEGFR inhibition.

mTOR-targeted inhibitor means a direct inhibitor of the protein called the mammalian target of rapamycin. Each of the following compounds is a non-limiting example of an mTOR-targeted inhibitor everolimus and temsirolimus.

ALKl Product means (i) anALKl (activin receptor-like kinase 1) polypeptide comprising a ligand binding portion of the extracellular domain of a vertebrate ALK 1, particularly human ALKl (e.g. a fusion protein including the ALKl ligand binding domain fused to an Fe p01iion of an IgG); (ii) an antibody that binds to the extracellular domain of human ALKl; (iii) an antibody that binds to human BMP9; or (iv) an antibody that binds to human BMPI0. For clarity, proteins that include the amino acid sequence described as SEQ ID NO 3 or SEQ ID NO5 in U.S. Patent No. 8,158,584 are included in the term ALKl Product.

RTKI means a small-molecule receptor tyrosine kinase inhibitor that binds to and inhibits signaling of VEGFRI, VEGFR2, or VEGFR3. An RTKI may, but need not, bind to and inhibit receptor tyrosine kinases in addition to a VEGFR, such as PDGFRa, PDGFRb, RET and c-Met. Likewise, an RTKI may, but need not, inhibit a different class of kinases that are not cell surface receptors, such as the serine kinases B-raf and c-raf kinase. Each of the following compounds is a non-limiting example of an RTKI sorafenib, pazopanib, axitinib, tivozanib, sunitinib, vandetanib, motesanib, vatalanib and samaxanib.

Field of Use
The Patented Use means the use of an ALKI Product and (i) an RTKI or (ii) an mTORtargeted inhibitor, for the treatment of patients with renal cell carcinoma. Patented Use shall include without limitation the sequential, overlapping or simultaneous dosing of patients with an ALKI Product and the RTKI or mTOR-targeted inhibitor. Patented Use shall also include any additional uses of ALKI Products that are the subject of a valid Claim of the Licensed Patents.

IPSCIO Record ID: 322039

License Grant
The parties collaborated to globally develop and commercialize Licensor’s ladiratuzumab vedotin (MK-6440). The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.

Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.

License Property
Ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors.

Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.

HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.

Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.

Field of Use
The field of use is for the treatment of cancer such as breast cancer.

HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).

Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.

IPSCIO Record ID: 284140

License Grant
Licensor granted Licensee worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.
License Property
Capmatinib is a potent and highly selective MET inhibitor. The investigational compound has demonstrated inhibitory activity in cell-based biochemical and functional assays that measure MET signaling and MET dependent cell proliferation, survival and migration.
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers.
Field of Use
Capmatinib is being evaluated in patients with hepatocellular carcinoma, non-small cell lung cancer and other solid tumors, and may have potential utility as a combination agent.

IPSCIO Record ID: 371771

License Grant
Licensor of Switzerland hereby grants to Licensee of Denmark (a) an exclusive, royalty-bearing, sublicensable assignable license under the Licensed Data and Product-Specific Patents and (b) a non-exclusive, royalty-bearing, sublicensable assignable license under the Platform Patents, in the case of (a) and (b) solely to Develop and otherwise Commercialize the Licensed Product in the Field in the Territory and to Manufacture and have Manufactured the Compound for use in a Licensed Product in the Field in the Territory as of the Effective Date.
License Property
Licensor own or control the certain Intellectual Property Rights (as defined below) Covering the Compound (as defined below) and has conducted Phase II Clinical Trials and Phase III Clinical Trials of the Compound for the treatment of gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), breast cancer, and other solid tumors.

Dovitinib is a pan-tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR) and other receptor tyrosine kinases (RTKs). Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells. In addition, this agent also inhibits other members of the RTK superfamily, including fibroblast growth factor receptor 1 and 3, FMS-like tyrosine kinase 3, stem cell factor receptor (c-KIT), and colony stimulating factor receptor 1. This may further lead to a reduction of cellular proliferation and angiogenesis, and an induction of tumor cell apoptosis.

TKI258 is a yellow to orange and/or brownish tinged, nonhygroscopic solid that dissociates into TKI258 free base and lactic acid between 125 to 250oC.

Platform Patents
PCT/US2003/010463

Product-Specific Patents
PCT/US2001/042131
PCT/EP2011/055906
PCT/EP2011/060949
PCT/US2013/023781
PCT/US2003/010463
PCT/US2012/029205

Field of Use
Field of use is for the treatment of Cancer.

IPSCIO Record ID: 183244

License Grant
Licensor granted an exclusive, worldwide license to develop and commercialize cerdulatinib in topical formulation for all indications, excluding oncology to German Licensee.
License Property
Cerdulatinib, is an orally available dual kinase inhibitor that inhibits spleen tyrosine kinase, or Syk, and Janus kinases, or JAK, enzymes that regulate important signaling pathways.  Cerdulatinib is being developed for hematologic, or blood, cancers and inflammatory disorders.
Field of Use
Licensee intends to develop it for the topical treatment of a range of dermatologic conditions.

This agreement is for the pharmaceutical industry, excluding oncology use.

IPSCIO Record ID: 26866

License Grant
The Company acquired from Licensor, an individual, the exclusive rights to two issued United States patents and one patent application pending in the United States covering (i) the use of adenosine 5-diphosphate (ADP) and adenosine 5-triphosphate (ATP) to arrest and kill tumor cells (United States patent issued November 1989); (ii) the arrest of growth of tumor cells due to an increase in blood and plasma levels of ATP in a host resulting from the administration to the host of adenosine monophosphate (AMP) or ATP and a reduction in weight loss caused by cancer cachexia by administration of AMP or ATP (United States patent issued September 1991); and (iii) the utilization of adenosine nucleotides and/or adenosine and inorganic phosphates for elevation of liver, blood and blood plasma ATP concentrations (United States patent pending).
License Property
ATP – a sterile formulation of adenosine triphosphate – under development for the treatment of solid tumors or cancer-related cachexia.
Field of Use
The product has completed one single-center Phase I and one multicenter Phase II clinical trial, and the Company believes the results support the continued investigation of the drug as an adjunctive therapy that may improve the quality of life in patients suffering from non-small cell lung cancer.

IPSCIO Record ID: 284321

License Grant
The parties agreed to have the Company develop Licensor’s pan-HER inhibitor, ARRY-543 (which the Company refers to as ASLAN001 or varlitinib), for the treatment or prevention of any disease or condition in humans, without upfront payments. Under the license agreement, the Company agreed to fund and globally develop ASLAN001 through proof of concept, initially targeting patients with gastric cancer through a development program conducted in Asia. Upon achievement of proof of concept, the Company agreed to collaborate or out-license to third parties for the further phase 3 development and commercialization.
License Property
ARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
Field of Use
ARRY-543 is currently entering Phase 2 development for solid tumors.

Licensee will fund and globally develop ARRY-543 through proof of concept, initially targeting patients with gastric cancer through a development program conducted in Asia.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.